Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 42 Rectal Neoplasms 31 Colorectal Neoplasms 31 Pancreatic Neoplasms 30 Neoplasms 26 Stomach Neoplasms 20 Neoplasm Metastasis 17 Colonic Neoplasms 13 Unspecified Adult Solid Tumor, Protocol Specific 12 Esophageal Neoplasms 12 Carcinoma, Non-Small-Cell Lung 11 Solid Tumor 7 Biliary Tract Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 4 Ovarian Neoplasms 4 Liver Neoplasms 4 Carcinoma, Hepatocellular 4 Bile Duct Neoplasms 4 Triple Negative Breast Neoplasms 3 Prostatic Neoplasms 3 Melanoma 3 Head and Neck Neoplasms 3 Gallbladder Neoplasms 3 Carcinoma, Renal Cell 3 Carcinoma, Ovarian Epithelial 3 Appendiceal Neoplasms 3 Anus Neoplasms 3 Adenocarcinoma 3 Vaginal Neoplasms 2 Uterine Cervical Neoplasms 2

Interventions

toripalimab 1 camrelizumab 1 Radiotherapy 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Advanced Tumors × Capecitabine × Clear all

NCT03781362 2022-07-20

Study of CPI-100 in Patients With Advanced Tumors

Coordination Pharmaceuticals, Inc.

Phase 1 Completed

Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡